-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Reiterates Buy on Neumora Therapeutics, Maintains $8 Price Target

Benzinga·03/31/2026 10:33:31
Listen to the news
Needham analyst Ami Fadia reiterates Neumora Therapeutics (NASDAQ:NMRA) with a Buy and maintains $8 price target.